Publications by authors named "Shirley P D'Sa"
Article Synopsis
- Bendamustine and rituximab (BR) therapy is effective for treating Waldenström Macroglobulinemia (WM), but the optimal dose of Bendamustine and its effects in different treatment settings remain unclear.
- In a study of 250 WM patients, response rates were significantly better in patients treated in the frontline setting compared to those with relapsed disease (91.4% vs 73.9%).
- Achieving a complete response (CR) or very good partial response (VGPR) improved survival rates, and higher doses of Bendamustine were linked to better progression-free survival (PFS) outcomes in both frontline and relapsed patients.
Background: Exercise programmes are beneficial for cancer patients however evidence is limited in patients with multiple myeloma (MM), a cancer that is characterised by osteolytic bone disease, giving rise to high levels of bone morbidity including fractures and bone pain.
Methods: We conducted a single arm phase 2 study of an exercise programme (EP) as rehabilitation for treated MM patients, to evaluate feasibility, effects on QOL and physiological parameters. Patients were given individualised programmes, comprising stretching, aerobic and resistance exercises, carried out under supervision for 3 months then at home for a further 3 months.